Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Highly Accessed Open Badges Research

Lack of association between a functional polymorphism (rs1800796) in the interleukin-6 gene promoter and lung cancer

Weihua Wang*, Jie Chen, Feng Zhao, Burong Zhang and Hongsheng Yu

Author Affiliations

The Affiliated Hospital of Medical College of Ningbo University, Ningbo 315020 Zhejiang, China

For all author emails, please log on.

Diagnostic Pathology 2014, 9:134  doi:10.1186/1746-1596-9-134

Published: 1 July 2014



A number of studies have examined the association between interleukin-6 (IL-6) rs1800796 polymorphism and risk of lung cancer but revealed inconsistent results. The aim of this study was to clarify the association between IL-6 rs1800796 polymorphism and risk of lung cancer.


Literature databases including PubMed, Embase and CNKI were searched up to January 2014. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) under co-dominant model, dominant model and recessive model were estimated using random-effects model.


A total of seven studies, including 2691 lung cancer cases and 3067 controls, were included in the meta-analysis. The results suggested that IL-6 rs1800796 polymorphism was not associated with risk of lung cancer under homogeneous co-dominant model (OR = 1.06, 95%CI = 0.73-1.54), heterogeneous co-dominant model (OR = 1.24, 95%CI = 0.96-1.60), dominant model (OR = 1.23, 95%CI = 0.95-1.58) and recessive model (OR = 0.96, 95%CI = 0.70-1.32). The association was still not significant in either never-smokers (OR = 1.19, 95%CI = 0.95-1.48) or ever-smokers (OR = 1.73, 95%CI = 0.89-3.36).


The present meta-analysis suggested that there was no association between IL-6 rs1800796 polymorphism and lung cancer, which was independent of smoking status.

Virtual Slides

The virtual slide(s) for this article can be found here: webcite

Interleukin-6; Lung cancer; Polymorphism; Meta-analysis